Thimble Point

Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. View more